Recent Company News

• 12:15 AM ET Oct 23, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:45 PM ET Oct 22, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 05:18 PM ET Oct 26, 2025
  

  ZAI Lab initiated buy at UBS (HK$21.56, 0.00)

• 10:09 PM ET Oct 24, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 12:14 PM ET Oct 24, 2025
  

  Transcript Intelligence: ZAI Lab at AACR NCI EORTC International Conference ($26.45, -1.57)

• 09:03 AM ET Oct 24, 2025
  

  Zai Lab announces updated Phase 1 data for zocilurtatug pelitecan (formerly ZL-1310); initiates global Phase 3 registrational study ($28.02, 0.00)

• 01:04 AM ET Oct 15, 2025
  

  argenx to present data on VYVGART, empasiprubart from 29-Oct through 1-Nov ($812.95, 0.00)

• 06:37 PM ET Oct 12, 2025
  

  Taiho Oncology & Cullinan Therapeutics present new data from CNS involvement cohort of REZILIENT2 study of zipalertinib in patients with advanced or metastatic NSCLC harboring EGFR ex20ins or uncommon non-ex20ins EGFR mutations at ESMO ($7.40, 0.00)